Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296512 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
A Phase 2 study of Gynecologic Cancer and Ovarian Clear Cell Carcinoma, sponsored by Elizabeth K. Lee MD.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT05296512: Active Phase 2 study of Gynecologic Cancer and Ovarian Clear Cell Carcinoma, sponsored by Elizabeth K. Lee MD.
NCT05296512 is a Phase 2 study of Gynecologic Cancer and Ovarian Clear Cell Carcinoma that is active but no longer recruiting, run by Elizabeth K. Lee MD. The registered enrollment target is 30 participants, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05296512, a Phase 2 study of Gynecologic Cancer and Ovarian Clear Cell Carcinoma, is active but no longer recruiting, sponsored by Elizabeth K. Lee MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer. The names of the study drugs involved in this study are: * Lenvatinib * Pembrolizumab
Primary Outcome
The objective response rate (ORR) is defined as the proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (3)
Illinois
- University of Chicago Medicine - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Comprehensive Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2028-11-15 |
| Phase | Phase 2 |
What the registry record for NCT05296512 still lists
NCT05296512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Gynecologic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05296512 reports a single indexed study location in Illinois, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05296512 about?
NCT05296512 is a clinical study titled "Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer". This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer. The names of the study drugs involved in this study are: * Lenvatinib * Pembrolizumab
What is the current status of trial NCT05296512?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-09-23. Estimated completion is 2028-11-15.
What conditions does trial NCT05296512 study?
This clinical trial studies the following conditions: Gynecologic Cancer, Ovarian Clear Cell Carcinoma.
What interventions are being tested in trial NCT05296512?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT05296512?
This trial is sponsored by Elizabeth K. Lee MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296512 being conducted?
This trial has 3 study locations across Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05296512's enrollment target sits among peer trials
30 43rd of 55 higher than 11 of 55 other Gynecologic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
RECRUITING · Phase 2
-
Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI